anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention comprises a composition comprising heat stable plant juice soluble plant proteins and a method of using the same for anti-pathogenesis effect. The said composition is standardized for a parameter of a property of the composition that is relatable to anti-pathogenesis property or to the content of the protein molecules having molecular weight of 26 kilo Daltons (kD) or less. The said anti-pathogenesis effect comprises an anti-microbial effect on living beings or as an Adiponectin agonist effect in mammals. The Adiponectin agonist effect in mammals comprises reducing the risk of one or more of a disorder selected from Type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity. The anti¬ microbial effect comprises reducing the risk of or treating the microbial infections in plants and animals, with or without synergistic interaction with other antimicrobial agents. This invention also comprises a plant material composition not containing, heat stable proteins; wherein the composition is made by pulping the plant material, removing juice from the solid residue, heating juice to remove coagulable protein and non-protein matter as a coagulum, removing the coagulum and thereafter removing the heat stable proteins from the resulting composition, optionally treating the same to get a further composition comprises either non-protein hydrophilic plant juice solubles or non-protein lipophilic plant juice solubles or both together in same composition.
A delivery system is disclosed for delivering a fluid-sensitive beneficial agent such as a somatotropin, or an analogue or derivative thereof, to an animal such as a bovine. The delivery system comprises a wall that surrounds an internal compartment, said wall comprising a first wall section that limits the passage of fluid into the system and a second wall section that permits the passage of fluid into the system. The wall may further comprise an end cap which may be adapted for ultrasonic welding to the first wall section and may maintain the beneficial agent in contact with an exit. The compartment comprises a beneficial agent and an expandable driving member. The delivery system comprises an exit for delivering the beneficial agent to the animal. The exit may compensate for slight variations in the efflux rate of the beneficial agent and maintain a sufficient velocity or efflux rate of beneficial agent outward from the device while minimizing diffusion of fluids from the external environment back into the device.
In clinical studies, finasteride, a component of ENTADFI, reduced serum PSA concentration by approximately 50% within six months of treatment. This decrease is predictable over the entire range of PSA values in patients with symptomatic BPH, although it may vary in individuals.

For interpretation of serial PSAs in men taking ENTADFI, a new PSA baseline should be established at least six months after starting treatment and PSA monitored periodically thereafter. Any confirmed increase from the lowest PSA value while on ENTADFI may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α-reductase inhibitor. Non-compliance with ENTADFI therapy may also affect PSA test results. To interpret an isolated PSA value in patients treated with ENTADFI for six months or more, double the PSA values for comparison with normal ranges in untreated men. These adjustments preserve the utility of PSA to detect prostate cancer in men treated with ENTADFI.

ENTADFI may also cause decreases in serum PSA in the presence of prostate cancer.

The ratio of free to total PSA (percent free PSA) remains constant even under the influence of ENTADFI. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men undergoing ENTADFI therapy, no adjustment to its value appears necessary.
PURPOSE:To homogeneously and stably blend gold leaves having a good influence on human bodies in a pack agent consisting essentially of polyvinyl alcohol, by using sodium carboxymethyl cellulose powdery agar and a carboxymethyl polymer, etc. CONSTITUTION:Gold leaves having effects, e.g. promotion of blood circulation and metabolism, enhancement of lymphous function, activation of nervous activity, etc., and passing through barrier zones of the skin and permeating to the subcutaneous tissues, etc., are blended in a pack agent. In the process, sodium carboxymethyl cellulose, seaweeds, e.g. powdery agar, etc., emulsifying agent, e.g. gelatin, stearin soap, etc., or a polymer, e.g. carboxymethyl polymer, etc., are blended to stabilize a fluid state, prevent movement of the gold leaves and promote homogenization and stabilization of the gold leaves without causing trouble in effects (effects on cutting off from air, peeling and stripping) as the pack agent.
HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
BACKGROUND/AIMS: Since the coronavirus disease 2019 (COVID-19) outbreak, hospitals have implemented infection control measures to minimize the spread of the virus within facilities. This study aimed to investigate the impact of COVID-19 on the incidence of healthcare-associated infections (HCAIs) and common respiratory virus (cRV) infections in hematology units.
METHODS: This retrospective study included all patients hospitalized in Catholic Hematology Hospital between 2019 and 2020. Patients infected with vancomycin-resistant Enterococci (VRE), carbapenemase-producing Enterobacterales (CPE), Clostridium difficile infection (CDI), and cRV were analyzed. The incidence rate ratio (IRR) methods and interrupted time series analyses were performed to compare the incidence rates before and after the pandemic.
RESULTS: The incidence rates of CPE and VRE did not differ between the two periods. However, the incidence of CDI increased significantly (IRR: 1.41 [p = 0.002]) after the COVID-19 pandemic. The incidence of cRV infection decreased by 76% after the COVID-19 outbreak (IRR: 0.240 [p < 0.001]). The incidence of adenovirus, parainfluenza virus, and rhinovirus infection significantly decreased in the COVID-19 period (IRRs: 0.087 [p = 0.003], 0.031 [p < 0.001], and 0.149 [p < 0.001], respectively).
CONCLUSION: The implementation of COVID-19 infection control measures reduced the incidence of cRV infection. However, CDI increased significantly and incidence rates of CPE and VRE remained unchanged in hematological patients after the pandemic. Infection control measures suitable for each type of HCAI, such as stringent hand washing for CDI and enough isolation capacities, should be implemented and maintained in future pandemics, especially in immunocompromised patients.
The invention relates to a preparation process of integration-type novel formulation of Cinnamomum cassia and Radix Glycyrrhizae decoction and a production method thereof. The effective components of the novel formulation are made from the following raw materials (by weight parts): Cinnamomum cassia twig 12 and processed Radix Glycyrrhizae 6. The production method includes the steps of supersonic airstream pulverization, alcohol-water extraction, ultrasonic pulverization and extraction, water decoction and concentration, supersonic spray-drying, nano-scale grinding, high-pressure emulsion and homogenization and nanoparticle preparation. The production method integrates the advantageous of the nano-carrier combination technique, such as multi-component synergism and multi-target. The large-scale production can greatly reduce the production cost, greatly improve the product quality and enhance the target property and sustained/controlled-release property of drugs. The novel formulation is administered by oral intake and external application during four time periods respectively based on the midnight-noon tidal flow and human qi-blood flow rule. The novel formulation is also processed to membranes and transdermal delivery agents which are applied to different parts of human body respectively according to the midnight-noon tidal flow and human qi-blood flow rule and can be directly absorbed by the skin.
Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, fruit juice (except apple juice) fruit punch, or in semi-solid food (for example, yogurt, pudding, or applesauce). The dose level for ataluren will be 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. Administration within 30 minutes after a meal will be recommended. Study drug dosing will be based on milligrams of drug per kilogram of body weight. Because of potential changes in participant body weight over time, weight-based dose adjustment can occur every 24 weeks as required. Study drug will be taken for up to 240 weeks.
In postmenopausal age, women bones get weak and easily fracture after 50years. In Pakistan every other female is silently suffering from this disease leading to bone, joint pain and disability. This project is innovatively designed first time in Pakistan to target weak bones of women with high intensity, progressive exercise training. The objectives of this study are to determine the effects of a high intensity multi-modal exercise training on bone mineral density and functional performance in postmenopausal women.

After initial screening based on history, subjective fracture risk calculations and subjective osteoporosis screening. Females fulfilling criteria and willing to participate in exercise trial will be recruited in the study. At baseline, DEXA scan will be done for Femoral and lumbar bone density. All performance based testing for functional performance outcome measures would be done at baseline, after 3 months \& after 6 months. Patient will be called twice a week for 8months and DEXA will be repeated after 8months of training. It is hypothesized that supervised exercise training will improve bone mineral density and functional performance in postmenopausal women with low bone mass.
The invention relates to notoginsenoside R1, in particular to application of notoginsenoside R1 in preparation of a medicine for preventing or treating non-alcoholic fatty liver disease. Experiments prove that the notoginsenoside R1 has a remarkable improvement effect on a mouse NAFLD model induced by methionine high-fat diet (CDAHFD) with deficiency of choline. The notoginsenoside R1 can effectively relieve liver morphological changes such as liver volume increase, surface roughness and the like, and improve liver lipid drop increase and fibrosis symptoms. In addition, notoginsenoside R1 can obviously reduce liver index; reducing serum transaminase (AST and ALT) levels, ameliorating liver damage; reducing liver lipid (TG and NEFA) content, and improving liver lipid accumulation. Meanwhile, notoginsenoside R1 exhibits strong anti-inflammatory and anti-fibrotic effects by inhibiting the expression of inflammation-related genes (Tgf-beta, il-1 beta and Tnf-alpha) and fibrosis-related genes (Acta 2 and Col1a 1). The invention provides a new strategy and thought for clinical treatment of NAFLD by using the notoginsenoside R1.
PURPOSE:To provide the titled composition having high safety, by suspending egg yolk in an organic solvent, separating the solid fraction from the suspension, removing the organic solvent from the resultant solution containing non-solidifying substance, and using a definite amount of the obtained fraction as an active component. CONSTITUTION:Egg yolk is suspended in an organic solvent (e.g. hexane, chloroform, etc.), and solid fraction is separated therefrom. The organic solvent is removed from the resultant solution containing non-solidifying substance and the obtained fraction is used as an active component of a composition having cholesterol level lowering or cholesterol level increase suppressing activity. The amount of the fraction is >=5wt% based on the whole composition. There is no limitation on the freshness of the egg yolk provided that the yolk is edible. The amount of the organic solvent is preferably 5-20pts. per 1pt. of the egg yolk. The composition is not only effective to hypercholesterolemia caused by various diseases such as arteriosclerosis, hyperlipemia, diabetes, etc., but also effective to suppress the increase of the blood cholesterol level of a healthy man caused by the intake of a food having high cholesterol content.
Adult patients of both sexes undergoing major lower abdominal cancer surgeries were enrolled in the study. After obtaining written informed consent from all the patients, they were randomly allotted to either Study (TAP) Group or Control group. Standard general anesthesia with endotracheal intubation was performed in all the patients. Preoperatively all patients received information about Visual Analogue Scale (VAS) for Pain Score from 1 to 10 depending on intensity of pain and about the use of Patient Controlled Analgesia (PCA) Pump. After the end of surgery and before extubation bilateral Ultrasound guided Transversus Abdominis Plane (TAP) block was performed with 16 G Tuohy needle and 18 G Braun Perifix epidural catheter was placed about 6-8 cms in situ. Bupivacaine 0.25 % 20 ml was given bilaterally and repeated 8 hourly in the Postoperative Anaesthesia Care Unit (PACU) for first 24 hours. The PCA Pump was set to deliver bolus Intravenous Morphine 1 milligram ( mg ) with lock out interval 10 minutes. In the PACU heart rate, Non invasive blood pressure, Visual Analogue Score at rest and on knee flexion, Sedation score, nausea and vomiting, any side effects as itching was noted by care provider at 0, 2, 4, 6, 12, 18 and 24 hours. Total and good PCA demands upto 24 hours was recorded.
BACKGROUND: The number of metastatic lymph nodes (MLNs) is crucial for the survival of nasopharyngeal carcinoma (NPC), but manual counting is laborious. This study aims to explore the feasibility and prognostic value of automatic MLNs segmentation and counting.
METHODS: We retrospectively enrolled 980 newly diagnosed patients in the primary cohort and 224 patients from two external cohorts. We utilized the nnUnet model for automatic MLNs segmentation on multimodal magnetic resonance imaging. MLNs counting methods, including manual delineation-assisted counting (MDAC) and fully automatic lymph node counting system (AMLNC), were compared with manual evaluation (Gold standard).
RESULTS: In the internal validation group, the MLNs segmentation results showed acceptable agreement with manual delineation, with a mean Dice coefficient of 0.771. The consistency among three counting methods was as follows 0.778 (Gold vs. AMLNC), 0.638 (Gold vs. MDAC), and 0.739 (AMLNC vs. MDAC). MLNs numbers were categorized into three-category variable (1-4, 5-9, > 9) and two-category variable (<4, ≥ 4) based on the gold standard and AMLNC. These categorical variables demonstrated acceptable discriminating abilities for 5-year overall survival (OS), progression-free, and distant metastasis-free survival. Compared with base prediction model, the model incorporating two-category AMLNC-counting numbers showed improved C-indexes for 5-year OS prediction (0.658 vs. 0.675, P = 0.045). All results have been successfully validated in the external cohort.
CONCLUSIONS: The AMLNC system offers a time- and labor-saving approach for fully automatic MLNs segmentation and counting in NPC. MLNs counting using AMLNC demonstrated non-inferior performance in survival discrimination compared to manual detection.
Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 4 channels of visual information, each of which represents a joint angle (right and left hips, right and left knees).
FIELD: medicine, urology. SUBSTANCE: invention proposes using bactisporin by oral route in the dose 2•10 9 -15•10 9  bacterial cells, 2-3 times per a day for 10-20 days. In the secondary pyelonephritis and on background of drainage systems bactisporin is administrated into pelvis cavity in the dose 1-5•10 9  bacterial cells additionally. In the secondary cystitis on the background of drainage systems bactisporin is administrated into bladder cavity in the dose 1-5•10 9  bacterial bodies. Method allows the prophylaxis in development of dysbacteriosis and allergic response reactions. Invention can be used in treatment of inflammatory diseases of organs of urinary system. EFFECT: enhanced effectiveness of treatment. 3 cl, 3 tbl, 4 ex
Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
Primary liver cancer (PLC) is the sixth most common malignancy in the world and the third most common cause of malignancy death. PLC mainly includes hepatocellular carcinoma (75%-85%) and intrahepatic cholangiocarcinoma (10%-15%). In 2020, there were about 905,677 new cases of PLC worldwide, and 830,180 deaths. Despite the availability of a variety of treatments for PLC, the 5-year net survival rate is still only 5% to 30%. How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide. Common risk factors for PLC include Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection, alcohol consumption, metabolic factors, etc. Although antiviral drugs can control or even cure chronic HBV and HCV to a certain extent, chronic viral infection is still the leading cause of PLC worldwide. In addition, with the prevalence of obesity, diabetes and non-alcoholic fatty liver disease (NAFLD), the incidence of non-infectious PLC is gradually increasing. In recent years, NAFLD has gradually become the leading cause of liver transplant waiting list for patients with hepatocellular carcinoma in the United States. The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different. Therefore, it is of great significance to fully identify the risk factors of PLC, be familiar with the clinical characteristics and prognosis of disease development, and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC. Currently, there are few large, single-center cohort studies on the clinical features and long-term prognosis of PLC.
Suppositories are formed from a mixture of insulin with a relatively large proportion of a non-irritant carrier and a small proportion of a non-irritant acid serving to protect the insulin against destruction by intestinal enzymes.  Surface-tension reducing agents may also be added to accelerate resorption of the insulin.  According to examples the carrier substance is cocoa butter, the acid is lactic acid or a mixture of lactic, citric and palmitic acids and the surface-tension reducer is a saponin. Other carriers referred to are low-melting fats, soaps, glycerol soap (fat, soap and glycerin), agar-agar, and gelatine; another suitable acid is tartaric acid; and other suitable surface-tension reducing substances are glycyrrhizines, soaps, soap-like sulphonated compounds, and alkali salts of naphthenic acids. Specifications 315,709, [Class 81 (i)], and 439,856 are referred to.  The Specification as open to inspection under Sect. 91 refers also to preparations containing a surface-tension reducing agent but no acid, and to the use of acetic acid.  This subject-matter does not appear in the Specification as accepted.
Cerebral blood flow (CBF) is normally autoregulated within a range of blood pressures, thus, allowing for a constant cerebral O2 supply commensurate with metabolic demands. The lower limit of blood pressure during general anesthesia deemed tolerable is usually empirically chosen without regard to an individual's lower autoregulatory threshold. This practice may lead to cerebral hypoperfusion in some patients placing them at risk for cerebral ischemic injury. This is particularly true during cardiac surgery using cardiopulmonary bypass where mean blood pressure is maintained at some level greater than 50 mm Hg or even lower during surgical mandated situations. This practice is concern for the rising number of aged surgical patients with cerebral vascular disease whom are prone to cerebral hypoperfusion. Individualizing blood pressure to be within the patient's autoregulatory range would more likely ensure adequate CBF during surgery. In this study we will evaluate whether real-time monitoring using a near infra-red spectroscopy (NIRS) based method accurately detects the lower CBF autoregulation threshold in patients compared with a validated, but technically more challenging method of CBF autoregulation measurement using transcranial Doppler. This approach involves continuous calculation of a moving linear regression correlation coefficient between blood pressure and cerebral O2 saturation measured with NIRS as a surrogate for CBF. A correlation coefficient, termed cerebral oximetery index, is generated and displayed versus blood pressure. When CBF is dysregulated, this correlation coefficient becomes markedly positive indicating CBF is pressure passive. We will further assess the added value of this type of monitoring to detect the lower CBF autoregulatory threshold compared with predictions based on preoperative blood pressure. These aims will be addressed in the study of 178 patients greater than 60 years of age undergoing coronary artery bypass graft surgery and/or valve surgery using cardiopulmonary bypass. Due to the many hemodynamic fluctuations during cardiac surgery, autoregulatory thresholds can be determined without administration of vasoactive drugs. Neurological complications are an important source of patient morbidity, mortality, hospital costs, and impaired quality of life after cardiac and other types of surgery. NIRS monitoring is non-invasive, continuous, requires little caregiver intervention and, thus, would have wide applicability for providing information about CBF autoregulation in a variety of clinical settings including cardiac surgery. This adoption could be enhanced with the likely development of "plug-and-play" monitors.